Literature DB >> 18822248

[Physiopathology of the diabetic foot].

D Malgrange1.   

Abstract

Diabetic foot ulcerations result from different physiopathological mechanisms; a clear understanding of them is crucial to reduce their incidence, provide early care, and finally delay the amputation risk. The three main diabetes complications involved in foot ulcerations are neuropathy, peripheral arterial disease, and infection. The most common pathway to ulceration is peripheral sensorimotor and autonomic neuropathy, leading to loss of sensitivity, foot deformities, high foot pressure, and dry skin. Peripheral arterial disease is more frequent and more serious in the diabetic population. It delays cicatrization and causes gangrene and finally amputation. Infection is also a major complication of ulceration because of its risk of spreading into deep tissue and bone, which increases the risk of amputation. Infection may also generalize and become life-threatening. These complications preferentially affect the foot because it is exposed to hyper pressure, neuropathy, and peripheral arterial disease, which cause distal lesions, and the foot is exposed to a closed atmosphere, a source of soaking and skin frailty. Diabetes itself may enhance the risk of complications stemming from the disease's long-term progression and poor glucose control, thereby affecting ocular and renal functions. Finally, some psychosocial situations such as depression syndrome or poor hygiene possibly enhance diabetic foot occurrence.

Entities:  

Mesh:

Year:  2008        PMID: 18822248     DOI: 10.1016/S0248-8663(08)73950-X

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  9 in total

1.  Advanced glycosylation end products (AGEs) controls proliferation, invasion and permeability through orchestrating ARHGAP18/RhoA pathway in human umbilical vein endothelial cells.

Authors:  Xu Li; Yue Tao; Xiaojun Wang; Tao Wang; Jianjun Liu
Journal:  Glycoconj J       Date:  2020-02-03       Impact factor: 2.916

Review 2.  Literature review on the management of diabetic foot ulcer.

Authors:  Leila Yazdanpanah; Morteza Nasiri; Sara Adarvishi
Journal:  World J Diabetes       Date:  2015-02-15

3.  Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers.

Authors:  M Erdogan; S Solmaz; A Canataroglu; M Kulaksızoglu; S Cetinkalp; A G Ozgen; F Saygili; C Yilmaz
Journal:  Endocrine       Date:  2010-04-14       Impact factor: 3.633

Review 4.  The role of endoplasmic reticulum stress in autoimmune-mediated beta-cell destruction in type 1 diabetes.

Authors:  Jixin Zhong; Xiaoquan Rao; Jun-Fa Xu; Ping Yang; Cong-Yi Wang
Journal:  Exp Diabetes Res       Date:  2012-02-14

5.  [Contribution of arterial Doppler ultrasound of the lower limbs in the treatment of diabetic foot at Saint-Jean de Dieu Hospital in Thies (Senegal)].

Authors:  Aliou Amadou Dia; Désiré Alain Affangla; Jean-Michel Dione; Géraud Akpo; Marie Mbengue; Mamadou Mourtalla Ka; Bernard Marcel Diop
Journal:  Pan Afr Med J       Date:  2015-10-27

6.  Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients.

Authors:  Yuriy K Bashmakov; Samir H Assaad-Khalil; Myriam Abou Seif; Ruzan Udumyan; Magdy Megallaa; Kamel H Rohoma; Mohamed Zeitoun; Ivan M Petyaev
Journal:  ISRN Endocrinol       Date:  2014-02-20

7.  [Approach to podiatric status of the diabetic patient in chronic hemodialysis in a Moroccan hospital].

Authors:  Nawal Benabdellah; Ilham Karimi; Yassamine Bentata; Intissar Haddiya
Journal:  Pan Afr Med J       Date:  2013-09-12

8.  [What agents incriminated in athlete's foot? Survey of consulting diabetic patients in CHU Mohammed VI Marrakech].

Authors:  Hakima Chegour; Nawal El Ansari; Ghizlane El Mghari; Abdelali Tali; Laila Zoughaghi; Majda Sebbani; Mohamed Amine
Journal:  Pan Afr Med J       Date:  2014-03-26

9.  [Podiatric risk screening in patients with type 2 diabetes in Antananarivo].

Authors:  Sitraka Angelo Raharinavalona; Haritsiky Robertini Ramalanjaona; Nalisoa Andrianera; Andrinirina Dave Patrick Rakotomalala; George Ramahandridona
Journal:  Pan Afr Med J       Date:  2017-07-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.